Clinical trial
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
NCT06737419 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 9, 2021
- Completion date
- February 5, 2024
- Enrollment
- 175 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.